Latest Valuation News

Pact Group Holdings Ltd has requested suspension of its shares from ASX trading as it prepares for removal from the official list, signaling a major shift for investors.

Alterity Therapeutics has responded to an ASX inquiry about its recent share price and volume spike, confirming no undisclosed information but highlighting imminent clinical data releases and investor roadshows as possible drivers.

Infini Resources is refining its exploration model at the Portland Creek Uranium Project after promising Phase 1 drilling results, setting the stage for a critical Phase 2 diamond drilling campaign in Q3 2025.

Platinum Capital Limited has unveiled a proposed restructure via a scheme of arrangement, offering shareholders the option to exchange their shares for units in the Platinum International Fund Complex ETF (PIXX). The move aims to address the persistent discount to net tangible asset value (NTA) and improve liquidity.

Platinum Asia Investments Limited (PAI) has announced a proposed restructure via a scheme of arrangement to exchange its shares for units in the Platinum Asia Fund Complex ETF (PAXX), aiming to resolve a persistent discount to net tangible asset value (NTA). The scheme, supported by independent directors and deemed fair by an expert, includes a potential special dividend and awaits shareholder and court approval.

Almonty Industries has had its trading suspension lifted following the release of an updated technical report on its Sangdong Project in South Korea, signaling renewed investor access and potential project reassessment.

RBR Group Limited has launched a Share Purchase Plan to raise up to $650,000, offering eligible shareholders shares at a notably low price of $0.001 each. The funds will support a joint venture, repay convertible notes, and bolster working capital.

Bryah Resources has exercised its option to acquire the Golden Pike gold and antimony project in New Brunswick, Canada, aiming to add significant value with a high-grade resource. The acquisition follows thorough due diligence and complements Bryah’s existing Australian portfolio.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing of Elate Ocular, a promising treatment for moderate to severe dry eye disease, pending additional financing.

Johns Lyng Group has entered a binding scheme implementation deed with Pacific Equity Partners for a $1.1 billion acquisition at $4.00 per share, representing a significant premium and a 10.3x EV/EBITDA multiple. The transaction awaits shareholder and regulatory approvals, with major shareholder backing and a clear timetable set for late 2025.

Argosy Minerals has completed a $2 million capital raising led by Evolution Capital, following an ASX inquiry into recent trading activity. The company affirmed the materiality of the placement and its compliance with continuous disclosure rules.

Whitefield Income Limited reported a steady net tangible asset backing of $1.26 per share for June 2025, alongside a robust fully franked dividend yield of 7.4%, maintaining its appeal to income-focused investors.